Glaxo believes that the worldwide consumer businesses will also have strong growth going forward with a rise in demand from an aging population and emerging middle class as they focus on health and wellness. Moreover, there is a sizable unmet need that will also drive the segment's business. The Consumer Health business of Glaxo and Pfizer has delivered 4% annual growth over the past two years. Glaxo believes that the complete focus of the standalone unit, following a demerger, on consumer businesses following the demerger will put it on a path of superior sales growth.